• Latest News

Galen attends the Royal College of Emergency Medicine annual scientific meeting 2019

Galen were this year’s platinum sponsors at the Royal College of Emergency Medicine annual scientific meeting in The Sage, Gateshead. The Galen Penthrox team spent three days with some of emergency medicine’s key opinion leaders in what was a truly excellent event. Galen provided speakers Dr Chris Moulton and Dr George Bailey to discuss...

Read more

NI Chamber Puts Dr Dennise Broderick under the Spotlight

Galen President and MD first keynote speaker in CEO Spotlight Series Craigavon, N.I., 7 Oct 2019 - Dr. Dennise Broderick, President and Managing Director of global speciality pharmaceutical company, Galen, was the first member to participate in Northern Ireland Chamber of Commerce and Industry’s CEO Spotlight Series. Supported by KPMG, the...

Read more

Dr Dennise Broderick, President and Managing Director of Galen, explains her commitment to driving growth with a strong focus on the customer and the patient.

Driving growth through patient focus Dr Dennise Broderick, President and Managing Director of Galen (a member of the Almac Group), explains her commitment to driving growth with a strong focus on the customer and the patient. Article published in : www.chemicalsknowledgehub.com, June/July 2019.  Galen, a Northern Irish based...

Read more

Galen Appoints Dr Dennise Broderick as Managing Director

15th January 2019 | Galen Ltd, the Northern Ireland based pharmaceutical company, is delighted to announce the appointment of Dr Dennise Broderick as its new Managing Director and President. She will report to Alan Armstrong, CEO and Chairman, Almac Group, - the parent company of Galen Ltd. Together with Almac Group’s Board of...

Read more

Galen expands further into US with significant acquisition

11th July 2013 | Galen Ltd, the Craigavon-based pharmaceutical company that is part of Almac Group, has reached a significant deal with a US company to acquire the rights to a leading medicinal product. Galen US, Inc., a wholly owned subsidiary of Galen Ltd, has entered into a product acquisition and license agreement with Nuvo...

Read more

Galen acquires Synera

11th July 2013 | SOUDERTON, PENNSYLVANIA Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin to provide local dermal analgesia for...

Read more

Would you like to discuss how Galen can help you?

If you would like to explore how Galen’s expertise could add value to your product, or for an initial discussion about partnering with us, please contact our team.